NCI Funds 4-Year Projects at 12 Tobacco Research Centers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 12
Volume 9
Issue 12

BETHESDA, Md-The National Cancer Institute (NCI) has launched its new antismoking initiative, Research in State and Community Tobacco Control Interventions, by awarding 12 grants totaling $13 million. The money will support the first year of 4-year research projects on local, state, and multistate tobacco prevention and control programs.

BETHESDA, Md—The National Cancer Institute (NCI) has launched its new antismoking initiative, Research in State and Community Tobacco Control Interventions, by awarding 12 grants totaling $13 million. The money will support the first year of 4-year research projects on local, state, and multistate tobacco prevention and control programs.

The first awards in the NCI program went to researchers at the University of Alabama at Birmingham; AMC Cancer Research Center, Denver; University of Illinois at Chicago; Battelle Centers for Public Health Research and Evaluation, Baltimore; and University of Massachusetts campuses at Amherst and Boston.

Grants also went to the University of Massachusetts Medical School; University of Minnesota School of Public Health; Roswell Park Cancer Institute; Oregon Research Institute, Eugene; Kaiser Permanente Center for Health Research, Portland, Oregon; and University of Texas Health Science Center at Houston.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content